HONG KONG – A green light to launch clinical trials in Canada for one of its leading biosimilar products will give South Korean company Alteogen Inc. and its Brazilian partner a boost on the global market.
HONG KONG – South Korean biopharma companies are urging the government to speed up the implementation of supporting policies, particularly tax policies that could make it easier for young bioventures to become competitive.
HONG KONG – South Korea's Samsung conglomerate is pouring tens of millions into Middle East respiratory syndrome (MERS) research, less than a year after an oversight at one of the company's hospitals facilitated the spread of the deadly virus.
HONG KONG – South Korea's Samsung conglomerate is pouring tens of millions into Middle East respiratory syndrome (MERS) research, less than a year after an oversight at one of the company's hospitals facilitated the spread of the deadly virus.
HONG KONG – South Korean biopharma companies are urging the government to speed up the implementation of supporting policies, particularly tax policies that could make it easier for young bioventures to become competitive.
HONG KONG – With the successful completion of a phase II study in the U.S. for its flagship product, VM202, for the treatment of critical limb ischemia (CLI), South Korean biopharma Viromed Co. Ltd. is off to a good start this year.
HONG KONG – The Korean Ministry of Food and Drug Safety (MFDS) is shortening the biologics review process for rare and incurable diseases to speed up the approvals and overseas distribution of Korea-developed biopharmaceuticals. Although details of the policy are sketchy and yet to be disclosed, the announcement marks the country's determination to make biopharmaceuticals a core industry.
